107 related articles for article (PubMed ID: 9337682)
21. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
Noguchi S; Yamamoto H; Inaii H; Koyama H
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
[TBL] [Abstract][Full Text] [Related]
22. Progestin as an alternative treatment option for multi-treated recurrent triple-negative breast cancer.
Xiangying M; Shikai W; Zefei J; Bing S; Yan M; Xin Z; Lijuan D; Yue W; Tao W; Shaohua Z; Santai S
Swiss Med Wkly; 2013; 143():w13765. PubMed ID: 23740185
[TBL] [Abstract][Full Text] [Related]
23. Assessment of five serum marker assays in patients with advanced breast cancer treated with medroxyprogesterone acetate.
Murray A; Clinton O; Earl H; Price M; Moore A
Eur J Cancer; 1995 Sep; 31A(10):1605-10. PubMed ID: 7488409
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
Etienne MC; Milano G; Frenay M; Renee N; Francois E; Thyss A; Schneider M; Namer M
J Clin Oncol; 1992 Jul; 10(7):1176-82. PubMed ID: 1535103
[TBL] [Abstract][Full Text] [Related]
25. Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.
Yunokawa M; Yoshida H; Watanabe R; Noguchi E; Shimomura A; Shimoi T; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Cancer Chemother Pharmacol; 2017 Jul; 80(1):127-134. PubMed ID: 28540420
[TBL] [Abstract][Full Text] [Related]
26. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
Yoshida M; Murai H; Miura S
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
[TBL] [Abstract][Full Text] [Related]
28. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
[TBL] [Abstract][Full Text] [Related]
29. Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system.
Abe O; Asaishi K; Izuo M; Enomoto K; Koyama H; Tominaga T; Nomura Y; Ohshima A; Aoki N; Tsukada T
Surg Today; 1995; 25(8):701-10. PubMed ID: 8520164
[TBL] [Abstract][Full Text] [Related]
30. A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
Kim R; Osaki A; Tanabe K; Kojima J; Toge T
Oncol Rep; 2001; 8(3):597-603. PubMed ID: 11295087
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of medroxyprogesterone acetate antineoplastic activity by histidine in rat mammary tumours.
Di Carlo F; Conti G; Giubertoni M; Muccioli G; Racca S
Cancer Chemother Pharmacol; 1991; 27(4):271-7. PubMed ID: 1825621
[TBL] [Abstract][Full Text] [Related]
32. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
Buchanan G; Birrell SN; Peters AA; Bianco-Miotto T; Ramsay K; Cops EJ; Yang M; Harris JM; Simila HA; Moore NL; Bentel JM; Ricciardelli C; Horsfall DJ; Butler LM; Tilley WD
Cancer Res; 2005 Sep; 65(18):8487-96. PubMed ID: 16166329
[TBL] [Abstract][Full Text] [Related]
33. Treatment of breast cancer with medroxyprogesterone acetate.
Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
[TBL] [Abstract][Full Text] [Related]
34. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study.
Kai K; Nishimura R; Arima N; Miyayama H; Iwase H
Int J Clin Oncol; 2006 Dec; 11(6):426-33. PubMed ID: 17180510
[TBL] [Abstract][Full Text] [Related]
35. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group.
Gundersen S; Kvinnsland S; Klepp O; Lund E; Hannisdal E; Høst H
Eur J Cancer; 1992; 28(2-3):390-4. PubMed ID: 1534248
[TBL] [Abstract][Full Text] [Related]
37. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
38. Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO).
Wander HE; Nagel GA; Blossey HC; Kleeberg U
Cancer; 1986 Nov; 58(9):1985-9. PubMed ID: 2944573
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.
Johnson JR; Priestman TJ; Fotherby K; Kelly KA; Priestman SG
Br J Cancer; 1984 Sep; 50(3):363-6. PubMed ID: 6235831
[TBL] [Abstract][Full Text] [Related]
40. [Progestational agents and bone metastasis in breast cancer].
Leriche N; Bonneterre J
Bull Cancer; 1997 Sep; 84(9):891-4. PubMed ID: 9435812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
